Added to YB: 2026-09-21
Pitch date: 2026-09-17
PRLD [neutral]
Prelude Therapeutics Incorporated
+6.33%
current return
Author Info
No bio for this author
Company Info
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Market Cap
$501.6M
Pitch Price
$4.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.12
P/E
-6.78
EV/Sales
16.39
Sector
Biotechnology
Category
special_situation
Biotech Conferences Week 2 Day 3 Part 2 - Prelude Therapeutics Incorporated
PRLD (quick overview): Prelude is presented as a legitimate strategic target or partner candidate, with a 75 M&A Score, but near-term value rests on PRT396 showing differentiated efficacy and tolerability before Incyte’s option window closes. Incyte paid $60M upfront and would pay $100M upon exercise, plus up to $775M in milestones and low-single-digit royalties. Initial Phase 1 data are expected in Q1 2027; the option expires in February 2027, potentially extendable to May, while efficacy, safety, and disease modification remain unproven.
Read full article (2 min)